Marburg, Germany, December 14, 2021

• GIANT-1 study to evaluate once-daily oral inhalation of novel catalytic antisense oligonucleotide formulation SB010 in patients with moderate to severe Type-2 driven asthma
• Standard of care remains insufficient for large number of these asthmatics
• Study incorporates digital therapy to enhance patient device handling, increase adherence, reduce drop-out rates and generate maximally reliable data through reduction of inter-patient variability

Marburg, Germany, November 23, 2021

• Phase IIa proof-of-concept (POC) study with novel catalytic antisense oligonucleotide SB010 in patients with moderate to severe asthma initiated.
• Innovative study design combines pharmacological therapy with VisionHealth’s Kata® Clinical, a unique combination of artificial intelligence, and computer animation to enhance patients’ device handling, adherence, reduce drop-out rates and generate maximally reliable data due to reduced inter-patient variability

Marburg, Germany, January 07, 2021

• Following successful completion of the company’s Series A – 1st closing with EUR 12.0 million in April 2020, sterna now has successfully completed a 2nd closing with another EUR 10.0 million, bringing the Series A total to EUR 22.0 million
• Proceeds from the 2nd closing will fund phase IIb preparatory activities including toxicology studies and CMC work for SB010 in moderate to severe asthma as well as the completion of an oral formulation project for SB012 laying the foundation for phase I/IIb studies in moderate to severe ulcerative colitis
• sterna’s approach to down-regulate master transcription factor GATA-3 using a DNAzyme (enzymatic antisense oligonucleotide) could provide a truly novel, first-in-class, broad-spectrum, non-steroidal, anti-inflammatory therapy across type 2 inflammatory diseases

Marburg, Germany, May 26, 2020

• Proceeds to fund next Phase 2 clinical study with SB010 in moderate to severe asthma and oral formulation work for SB012 in ulcerative colitis 
• Sterna’s approach to down-regulate master transcription factor GATA-3 using a DNAzyme (enzymatic antisense oligonucleotide) enables broad-spectrum, simultaneous intervention in key type 2 inflammatory processes 
• Topical treatment with SB010 and SB012 is expected to become a novel, safe and efficacious therapeutic option for chronic inflammatory diseases with high unmet medical need.